ZIC1 Is Downregulated through Promoter Hypermethylation, and Functions as a Tumor Suppressor Gene in Colorectal Cancer by Gan, Lihong et al.
ZIC1 Is Downregulated through Promoter
Hypermethylation, and Functions as a Tumor Suppressor
Gene in Colorectal Cancer
Lihong Gan
1., Shujie Chen
2., Jing Zhong
1, Xian Wang
3, Emily K. Y. Lam
4, Xin Liu
4, Jianbin Zhang
4,
Tianhua Zhou
5, Jun Yu
4, Jianmin Si
2, Liangjing Wang
1*, Hongchuan Jin
3
1Department of Gastroenterology, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, 2Laboratory of Digestive Disease, Clinical
Institution of Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China, 3Key Laboratory of Biotherapy of Zheijang Province, Biomedical Research Center, Sir Run
Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China, 4Department of Medicine and Therapeutics, Institute of Digestive Disease, Prince of Wales
Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR China, 5Department of Cell Biology and Program in Molecular Cell Biology, School of Medicine
Zhejiang University, Hangzhou, China
Abstract
The transcription factor, Zinc finger of the cerebellum (ZIC1), plays a crucial role in vertebrate development. Recently, ZIC1
has also been found to participate in the progression of human cancers, including medulloblastomas, endometrial cancers,
and mesenchymal neoplasms. However, the function of ZIC1 in colon cancer progression has not been defined. In this
study, we demonstrate ZIC1 to be silenced or significantly downregulated in colon cancer cell lines. These effects were
reversed by demethylation treatment with 5-aza-29-deoxycytidine (Aza). ZIC1 expression is also significantly downregulated
in primary colorectal cancer tissues relative to adjacent non-tumor tissues (p=0.0001). Furthermore, methylation of ZIC1
gene promoter is frequently detected in primary tumor tissues (85%, 34/40), but not in adjacent non-tumor tissues. Ectopic
expression of ZIC1 suppresses cell proliferation and induces apoptosis, which is associated with MAPK and PI3K/Akt
pathways, as well as the Bcl-xl/Bad/Caspase3 cascade. To identify target candidates of ZIC1, we employed cDNA microarray
and found that 337 genes are downregulated and 95 genes upregulated by ectopic expression of ZIC1, which were verified
by 10 selected gene expressions by qRT-PCR. Taken together, our results suggest that ZIC1 may potentially function as a
tumor suppressor gene, which is downregulated through promoter hypermethylation in colorectal cancers.
Citation: Gan L, Chen S, Zhong J, Wang X, Lam EKY, et al. (2011) ZIC1 Is Downregulated through Promoter Hypermethylation, and Functions as a Tumor
Suppressor Gene in Colorectal Cancer. PLoS ONE 6(2): e16916. doi:10.1371/journal.pone.0016916
Editor: Irina Agoulnik, Florida International University, United States of America
Received October 10, 2010; Accepted January 3, 2011; Published February 15, 2011
Copyright:  2011 Gan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by the National Natural Scientific Foundation of China (30900676), the Natural Scientific Foundation of Zhejiang Province of
China (Y206280), and the Department of Science and Technology of Zhejiang Province of China (2009C03012-3). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Wanglj76@hotmail.com
. These authors contributed equally to this work.
Introduction
Colorectal cancer (CRC) is the third most common cancer, as well
as the third leading cause of cancer deaths worldwide [1]. The
sequential accumulation of genetic and epigenetic alterations leads to
the transformation of normal colonic epithelium to colorectal cancer
[2]. These epigenetic changes, including promoter DNA methylation
and histone modifications, can induce the inactivation of tumor
suppressor genes (TSGs) [3–5]. DNA regions enriched with CpG
dinucleotides, called CpG islands, can become hypermethylated in
cancer cells and result in the silencing of TSGs [5]. A subset of CRCs
display methylation of multiple genes, termed the CpG island
methylator phenotype (CIMP) [2,5]. We and others have previously
found that growing numbers of TSGs including APC, CDKN2A/
p16, UCHL1, and TBX5 are frequently silenced through promoter
hypermethylation in CRCs [2,6–9]. These events can occur in early
stage of CRCs [9,10], which highlights the importance of promoter
hypermethylation in the tumorigenesis of CRCs.
Located at chromosome 3q24, ZIC1 encodes a C2H2-type zinc
finger transcription factor that plays a critical role in the
development of the neural crest and the cerebellum in vertebrates
[11–15]. As zinc finger transcription factors, ZIC family proteins
can bind to the GC-rich sequence in target genes [15]. Despite its
role in neural development, ZIC1 was also found to participate in
the progression of human cancers, such as medulloblastoma,
endometrial cancers, and mesenchymal neoplasms [16–18]. We
have identified ZIC1 as a novel candidate TSG in gastric cancer
[19]. To support its role in cancer, ZIC1 can function as a
repressor of the downstream target of sonic hedgehog (Shh), BMP
(bone morphogenetic protein), and as well as play a role in Notch
signaling pathway during neural tube development [14,15].
However, the biological significance of DNA methylation, and
the molecular mechanism underlying ZIC1 functioning as a TSG
in CRCs remain unknown. Here, we report that ZIC1 promoter is
frequently methylated in CRCs tissues and colon cancer cell lines.
Ectopic expression of ZIC1 leads to cell growth inhibition, and
alter the expression of potential target genes that may play
important roles in colorectal carcinogenesis. Our results suggest
that ZIC1 may potentially function as a novel functional tumor
suppressor in CRCs.
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16916Results
Transcriptional silencing of ZIC1 is associated with its
promoter hypermethylation in colon cancer cells
To determine whether ZIC1 is silenced by promoter hypermethy-
lation in colon cancer, we examined the expression of ZIC1 mRNA
in six colon cancer celllines.Semi-quantitativeRT-PCR showed that
ZIC1 transcript was silenced or downregulated in all of colon cancer
cell lines when compared to normal colon tissue (Figure 1A). The
demethylation treatment by Aza dramatically restored the expression
of ZIC1 mRNA in a subset of colon cancer cells (HCT116, HT29
and SW620) (Figure 1B), implicating that DNA methylation may be
involved in the regulation of ZIC1 expression. Furthermore, we
employed methylation specific PCR (MSP) and found that three
colon cancer cell lines (HCT116, DLD1 and SW620) were detected
with full methylation. The other three cell lines (HT29, LS180 and
SW480) were found with partial methylation. No methylation was
detected in the normal colon tissues (Figure 1C). Thus, these results
indicate that transcriptional silence of ZIC1 in colon cancer cell lines
may be mediated by DNA promoter hypermethylation.
Downregulation and promoter hypermethylation of ZIC1
in primary colorectal tumors
To further investigate the relationship between ZIC1 expression
and promoter hypermethylation, we analyzed ZIC1 mRNA
expression and CpG site methylation status in primary colorectal
tumor and adjacent non-tumor tissues by qRT-PCR and MSP,
respectively. The level of ZIC1 mRNA was significantly decreased
in most tumor tissues relative to adjacent non-tumor tissues
(p=0.0001, n=24) (Figure 2A). Additionally, promoter methyl-
ation was detected in 85% (34/40) of colorectal tumor tissues, but
not in adjacent non-tumor tissues by MSP analysis (the
representative data shown in Figure 2B), implying a tumor-
specific hypermethylation of the ZIC1 promoter in CRCs.
However, we failed to find a significant correlation between
ZIC1 promoter methylation and clinical characteristics, such as
age, gender, tumor differentiation, and TNM stage (Table 1).
ZIC1 inhibits the proliferation of colon cancer cells
To explore the effect of ZIC1 on cell proliferation in colon
cancer, we performed cell viability and colony formation assays in
CRC cell lines. First, the transfection efficiency of our ZIC1
construct was confirmed by RT-PCR and western blot in tumor cell
lines (HCT116 and HT29) (Figure 3A). Next, we evaluated the
suppressive effect of ZIC1 overexpression on cell proliferation by
cell viability assay. As shown in Figure 3B, ectopic expression of
ZIC1 significantly inhibited cell viability in HCT116 and HT29
cells (p,0.05). We also observed that the number of surviving
colonies formed on the plates was significantly reduced when
compared with the control vector transfectants (p,0.01)
(Figure 3C). In addition, we revealed that ectopic expression of
ZIC1 inhibited the phosphorylation of Erk1/2 and Akt kinases
(Figure 3D), two key cell proliferation pathway regulators. These
results confirmed thesuppressiveeffect ofZIC1 oncellproliferation.
Ectopic expression of ZIC1 induces cell apoptosis
To explore the mechanisms underlying the inhibition of cell
proliferation by ectopic expression of ZIC1, we analyzed cell
apoptosis and cell cycle by flow cytometry assay. As shown in
Figure 4A, the cells transfected with ZIC1 induced cell apoptosis.
In addition, our results showed that re-expression of ZIC1 led to
the activating of apoptosis-related cascades, including cleavage of
caspase3, downregulation of Bcl-xl, and Bad dephosporylation
(Figure 4B). These results indicate that the induction of cell
apoptosis through overexpression of ZIC1 is mediated by the Bcl-
xl/Bad/Caspase3 cascade. However, re-expression of ZIC1 did
not affect cell cycle progression (data not shown).
Gene expression profile changes by ectopic exogenous
ZIC1 expression
To search for target genes of ZIC1 in colon cancer cells, we
utilized cDNA microarray to analyze gene expression profile
changes induced by ectopic expression of ZIC1. This analysis
revealed that 337 genes were downregulated and 95 genes were
upregulated by exogenic expression of ZIC1 when using a 2-fold
change of expression as threshold (representative genes shown in
Figure 5A). As shown in Table 2, many of these genes have been
reported to play important roles in cell proliferation and apoptosis.
To confirm the expression pattern observed in the microarray, we
validated the expression of 10 selected genes in colon cancer cells
transfected with ZIC1 by qRT-PCR. The results showed that
CCNA2 (cylin A2) and IGFBP3 (insulin-like growth factor binding
Figure 1. Promoter methylation contributes to ZIC1 downregulation in colon cancer cell lines.( A) The expression of ZIC1 is silenced or
downregulated in colon cancer cell lines, when compared with normal colon tissue by RT-PCR. GAPDH was used as the internal control. Normal
colon: Normal colon tissues. (B) ZIC1 expression is restored in colon cancer cells (HCT116, HT29 and SW620) after treatment with demethylation
agent 5-Aza by RT-PCR. AZA: 5-aza-29-deoxycytidine. (C) The methylation status of ZIC1 CpG promoter is detected by methylation-specific PCR (MSP)
in colon cancer cell lines. M: methylated; U: unmethylated.
doi:10.1371/journal.pone.0016916.g001
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whereas ANGPT2 (angiopoietin 2), GADD45B (growth arrest and
DNA-damage-inducible, beta), LAMB2 (laminin, beta 2), LAMB3
(laminin, beta 3), MALAT1 (metastasis associated lung adenocar-
cinoma transcript 1), PNMA2 (paraneoplastic antigen MA2), RPA4
(replication protein A4), and TACSTD2 (tumor-associated calcium
signal transducer 2) (,22 fold change) were downregulated by
overexpression of ZIC1 in HCT116 and HT29 cells (Figure 5B
and Table S1). These data were concordant with that obtained
from the microarray analysis.
Discussion
In the present study, we found that ZIC1 was silenced or
downregulatedincoloncancercell lines,aswell asinprimarytumor
tissues relative to adjacent non-tumor tissues (p,0.05). Further-
more, our observations identify that promoter DNA hypermethyla-
tion contributes to ZIC1 silencing or downregulation in CRCs.
These results are consistent with our previous study of ZIC1 in
gastric cancer [19], indicating that promoter CpG methlyation is
the predominant mechanism for ZIC1 downregulation. However,
we cannot exclude the appearance of other mechanisms in silencing
of ZIC1, such as histone or nucleosome remodeling. For instance,
ZIC1 expression failed to be restored after Aza treatment in LS180
and SW480 cell lines (data not shown). Recent studies illustrate that
methylation of histone H3 at lysine 27 is linked to ZIC1 silencing in
embryonic stem cells [18]. Chromatin immunoprecipitation assays
show that the expression of ZIC1 is associated with histone H3
dimethylation at lysine 4 in desmoids and MEF cells [18].
Despite the illustration of the critical role of ZIC1 in vertebrate
development [13,15], functional characterization of ZIC1 in
carcinogenesis remains largely unknown. Here, our results show
that exogenous ZIC1 inhibits cell proliferation through p-Akt and
p-Erk1/2 inactivation in colon cancer cells. PI3K/Akt and MAPK
(Mitogen activated protein kinase) signaling pathways are well
known to function as crucial components of cell proliferation in
tumor cells [20,21]. Akt and Erk1/2, once activated by
phosphorylation, can function as key effectors of PI3K and MAPK
signaling pathways to promote cell survival and proliferation [20–
24]. Thus, ZIC1 may mediate cell proliferation through PI3K/Akt
and MAPK pathways in colon cancer cells. In addition, we found
that ectopic expression of ZIC1 can induce apoptosis of colon
cancer cells. Among the wide spectrum of proteins and genes
involved in apoptosis, members of the Bcl-2 family play a central
role in this process [25,26]. Caspase-3 has been identified as being
a key mediator of apoptosis in mammalian cells, and the
phosphorylation of Bad can block its apoptotic function
[22,25,26]. In this regard, we found that the expression of
cleaved-caspase3 and Bad were induced, while phospho-Bad and
Bcl-xl were suppressed by re-expression of ZIC1. Our results
suggest that induction of apoptosis by ZIC1 may be associated
with Bcl-xl/Bad/Caspase3 cascade in colon cancer cells.
In an attempt to identify downstream targets of ZIC1 in CRCs, we
analyzed the gene expression profiles of colon cancer cells with or
without ZIC1 overexpression. The results revealed that 337 genes
were downregulated and 95 genes were upregulated by ZIC1
(representative novel genes shown in Table 2). Many of these genes
have been linked to cellular growth, apoptosis, adhesion, angiogen-
esis, and signal transduction in tumorigenesis [27–33]. For example,
ZIC1 repressed the expression of GADD45B.GADD45B is induced by
the activation of the p38/JNK (c-Jun N-terminal kinase) pathway
[27], and an important mediator of NF-kB-JNK crosstalk and cell
apoptosis [28]. JNK is another major downstream component of the
MAPK cascades, and is associated with cell growth and cellular
response to DNA damage [21,23,24]. In addition, we found that
ZIC1 increased the expression of RSU1 (Ras suppressor protein 1),
which is reported to elevate the levels of p21
CIP CDK inhibitor, as
Figure 2. Downregulation of ZIC1 expression and frequent
hypermethylation of ZIC1 promoter in primary colorectal
tumor tissues. (A) ZIC1 mRNA expression was determined by
quantitative real-time PCR in twenty four pairs of primary colorectal tumor
and according adjacent non-tumor tissues. The data was analyzed by
Wilcoxon matched pairs test. (B) The methylation status of ZIC1 promoter
in primary colorectal carcinoma and adjacent non-tumor tissues was
determined by MSP. Representative image are shown. T: tumor tissues; N:
adjacent non-tumor tissues; M:m e t h y l a t e d ;U: unmethylated.
doi:10.1371/journal.pone.0016916.g002
Table 1. Clinicopathological features of ZIC1 methylation in
colorectal cancer.
Characteristics Methylated (n) Unmethylated (n) P-value
Age, years(6SD) 60.6613.1 60.265.1 0.939
Gender 0.489
Male 19 4
Female 15 2
Differentiation 0.398
Well 21 3
Morderate 12 2
Poor 1 1
TNM Stage 0.315
I3 2
II 14 3
III 16 1
IV 1 0
doi:10.1371/journal.pone.0016916.t001
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stimulation [29]. With our finding of ZIC suppression of p-Erk1/2,
we propose that ZIC1 can regulate MAPK pathways mediated by
ERK and JNK kinases. Further study is required to illustrate the
mechanisms by which ZIC1 regulates these potential pathways in
cancer progression. Furthermore, we demonstrated that ZIC1 can
suppress the expression of other novel genes (TACSTD2, ANGPT2,
LAMB2, LAMB3 and MALAT1 etc.) related to tumor angiogenesis
and metastasis. TACSTD2 h a sb e e nf o u n da s s o c i a t e dw i t ht u m o r
aggressiveness and poor prognosis in epithelial cell tumors, including
Figure 3. ZIC1 inhibits the proliferation of colon cancer cell and regulates MAPK, PI3K/Akt pathways. (A) Re-expression of ZIC in stable
transfectants in colon cancer cells (HCT116 and HT29) was confirmed by RT-PCR (upper lane) and western blot (low lane), GAPDH and b-actin used as
internal control. (B) Cell viability assay after ZIC1 re-expression in colon cell lines (HCT116 and HT29). The number of viable cells was measured by
MTS assay after transiently transfected with pCDNA3.1-ZIC1 or pCDNA3.1 vector. The assay was performed in triplicate. The asterisk indicates
statistical significance (p,0.05). (C) The effect of cell proliferation inhibition by ectopic expression of ZIC1 was determined by colony formation assay
in colon cancer cells. The quantitative analysis of colony numbers formed in pCDNA3.1-ZIC1 or pCDNA3.1 vector transfectants are shown in right bar
diagram in three individual experiments in HCT116 and HT29 cells. The asterisk indicates statistical significance (p,0.05). (D) The expression phos-Akt
and phos-Erk1/2, as well as the total of Akt and Erk1/2 were analyzed by western blot. Band densities were quantified and protein levels (p-Akt, p-
Erk1/2) were normalized to b-actin. Densitometry values (ZIC1 transfectants) are expressed as fold change compared with vector transfectants values
normalized to 1.
doi:10.1371/journal.pone.0016916.g003
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detected by the Annuexin V-PI flowcytometry assay. The representative figures are shown after transiently transfected with ZIC1 or control vector
after 48 hours in HT29 and HCT116 cells. Region A1 indicates early apoptotic cells, A2 shows late apoptotic cells. (B) Western blot analysis of
apoptotic regulated proteins. The expression of phospho-Bad and Bad, Bcl-xl, Cleaved-caspase3, and Caspase3 were detected after transected with
ZIC1 or control vector in colon cancer cell lines (HT29 and HCT116). Band densities were quantified and protein levels (p-Bad, Bad, Bcl-xl, and Cleaved-
caspase3) were normalized to b-actin. Densitometry values (ZIC1 transfectants) are expressed as fold change compared with vector transfectants
values normalized to 1.
doi:10.1371/journal.pone.0016916.g004
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regulator of vascular remodeling during tumor angiogenesis [32,33].
Aszinc finger transcriptionfactors, the ZICfamilyofproteinscan
bind to GC-rich sequences in target genes [13,15]. ZIC1 may
regulate target genes in both sequence-specific and sequence-
independent manners [15]. Depending on its interaction partners,
ZIC proteins can activate or suppress the transcription of target
genes. As expected, we observed that ZIC1 regulated the expression
of important transcription factors such as RPS2, NTF3, PRDM16,
KLF15, SHC2 and FOXJ1 (Table S2). ZIC1 has been shown to
counteract with Gli (glioma-associated oncogene homolog 1), which
functions as downstream of sonic hedgehog (Shh) signaling pathway
and participate in the progression of colon cancer [34–36].
Meanwhile, numerous of downstream targets of ZIC1 including
Notch, Cyclin D1, and Wnt3a have been reviewed in neural
development and animal models [15,37]. These genes are well
known to play vital roles in cancer development. The study of ZIC1
target genes may provide further insight into the possible
mechanisms of ZIC1 serving as a tumor suppressor in CRCs.
In summary, we revealed that a novel tumor suppressor gene
ZIC1 was inactivated through promoter methylation in colon
cancer cells. ZIC1 was also downregulated and frequently
hypermethylated in primary colorectal cancer tissues. ZIC1
inhibits cell proliferation through suppression of PI3k and MAPK
pathways, induction of cell apoptosis through the Bcl-xl/Bad/
Caspase3 cascade, regulation of downstream targets and pathways
implicated in colorectal carcinogenesis.
Materials and Methods
Cell culture and tissue specimens
The human colon cancer cell lines (HCT116, HT29, DLD1,
LS180, SW480 and SW620) were obtained from Riken Gene
Bank (Japan) and American Type Culture Collection (ATCC,
USA). HCT116 cell line was cultured in McCoy’s 5A medium
(Invitrogen, USA) supplemented with 10% fetal bovine serum, all
other cell lines were cultured in DMEM medium (Invitrogen,
USA) supplemented with 10% fetal bovine serum. All cell lines
incubated at 5% CO2,3 7 uC and 95% humidity.
Forty surgical resected colorectal adenocarcinomas and adja-
cent non-tumor specimens were obtained from Sir Run Run Shaw
Hospital, School of Medicine Zhejiang University. CRC was
classified according to International Union Against Cancer
Criteria and staged with the tumor-node-metastasis (TNM)
system. Specimens were immediately frozen in liquid nitrogen
and stored in 280uC until further processing. All patients
provided informed written consent for obtaining the study
specimens. The study protocol was approved by the Clinical
Research Ethics Committee of Sir Run Run Shaw Hospital.
Pharmacological DNA demethylation with 5-Aza-29-
Deoxycytidine
Cells were treated for 72 hours with 5 mM5 - aza-29-deoxycytidine
(Aza) (Sigma, St Louis, MO, USA), a well-used methyltransferase
inhibitor. Aza was replenished every 24 hours. An equivalent
concentration of the vehicle (DMSO) was used as the control.
RT-PCR and quantitative PCR analysis
Total RNA (1 mg) was extracted using Trizol reagent (Invitro-
gen) following manufacturer’s instruction, then reverse transcribed
into cDNA with High-capacity cDNA Reverse Transcription kit
(Applied Biosystems). RT-PCR was carried out for 35 cycles (95uC
for 30 s, 55uC for 30 s, 72uC for 30 s). PCR product was
electrophoresed in 2% agarose and stained with ethidium
bromide. Quantitative real-time PCR (qRT-PCR) was performed
with the SYBR Green Master Mix kit (Takara,Japan) in ABI 7500
Figure 5. The validation of ZIC1 regulating target genes. (A) The differential expression of gene profiles in ZIC1 or control vector stable
transfectants was visualized using Java Treeview in HCT116 cell lines. Representative genes over two-fold change are indicated on the right side of
this image. (B) Genes transcript quantity of 10 selected genes was measured by qRT-PCR and calculated using the value of 2
2ggCT. Relative gene
expression in ZIC1 transfectants was compared with empty control vector, which was normalized as a reference value of 1.0. White bars indicate the
result of microarray analysis, and black bars representative of qRT-PCR data in HCT116 cell line.
doi:10.1371/journal.pone.0016916.g005
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house keeping gene (GAPDH) using the 2
2DDCt method. All
primers sequences were listed in Table S3.
Bisulfite treatment of DNA and methylation specific PCR
(MSP)
Genomic DNA (1 mg) was bisulfite-treated with Zymo DNA
modification Kit (Zymo Research, USA). Methylation status of
ZIC1 was detected by methylation-specific PCR (MSP) using the
bisulfite treated genomic DNA as the template. MSP was carried
out for 40 cycles with annealing temperature at 60uC, as
previously described [38,39]. Methylation (M) primers were: F
59-GGATTTTTTGTTTCGTAATC, R 59-CCCGTTAACC-
ACGTTAAACG, and Unmethylation (U) primers were: F 59-
GGGATTTTTTGTTTTGTAATT, R 59-CCCATTAACCA-
CATTAAACA.
Cell transfection and cell viability assay
To construct a ZIC1 expression plasmid, the full-length ZIC1
open reading frame was cloned into mammalian expression vector
pCDNA3.1 as previous described [19]. To generate stable
transfection cells, HCT116 and HT29 cells were transfected with
pCDNA3.1-ZIC1 or pCDNA3.1 vector using Lipofectamine 2000
(Invitrogen), and selected by G418 (400 mg/ml) for 14 days in a
Table 2. Representative gene expression profile in ZIC1 transfectants compared with empty vector control (fold change) by cDNA
microarray in HCT116 cells.
Gene Symbol Gene Description
Genbank
Accession
Fold
Change (*) Gene Function
Down
-Regulation
cell proliferation, apoptosis,
migration, adhesion, and
angiogenesis
ANGPT2 angiopoietin 2 NM_001147 0.43 angiogenesis
AOC3 amine oxidase, copper containing 3 NM_003734 0.48 cell adhesion
AVIL advillin NM_006576 0.47 cell migration
COL20A1 collagen, type XX, alpha 1 NM_020882 0.37 cell adhesion
CTGF connective tissue growth factor NM_001901 0.43 cell proliferation/angiogenesis
CYR61 cysteine-rich, angiogenic inducer, 61 NM_001554 0.42 cell proliferation/cell adhesion
DLEC1 deleted in lung and esophageal cancer 1 NM_007335 0.45 cell proliferation
EFNB3 ephrin-B3 NM_001406 0.47 cell differentiation
GADD45B growth arrest and DNA-damage-inducible, beta NM_015675 0.5 cell proliferation/cell apoptosis
KRT14 keratin 14 NM_000526 0.48 epithelial cell differentiation
LAMB2 laminin, beta 2 (laminin S) NM_002292 0.5 cell adhesion/cell migration
LAMB3 laminin, beta 3 NM_001017402 0.39 cell adhesion/cell migration
MALAT1 metastasis associated lung adenocarcinoma transcript NR_002819 0.2 cell proliferation/metastasis
MLXIPL MLX interacting protein-like NM_032951 0.5 cell proliferation
OSM oncostatin M NM_020530 0.49 cell proliferation
PNMA2 paraneoplastic antigen MA2 NM_007257 0.33 cell proliferation
PTPRH protein tyrosine phosphatase, receptor type, H NM_002842 0.44 cell apoptosis
RPA4 replication protein A4, 34 kDa NM_013347 0.37 cell proliferation
SNIP Smad nuclear interacting protein 1 NM_025248 0.46 cell migration
TACSTD2 tumor-associated calcium signal transducer 2 NM_002353 0.49 cell proliferation
Up
-Regulation
cell proliferation, apoptosis,
migration, adhesion, and
angiogenesis
CCNA2 cyclin A2 NM_001237 2.02 cell proliferation
CDCA3 cell division cycle associated 3 NM_031299 2.07 cell proliferation
ESCO2 establishment of cohesion 1 homolog 2 NM_001017420 2.43 cell proliferation
IBSP integrin-binding sialoprotein NM_004967 2.11 cell adhesion
IGFBP3 insulin-like growth factor binding protein 3 NM_001013398 2.27 cell proliferation/cell apoptosis
NRP1 neuropilin 1 NM_003873 2.47 cell adhesion/angiogenesis
ORC1L origin recognition complex, subunit 1-like NM_004153 2.34 cell proliferation
PLEKHK1 rhotekin 2 BC025765 2.03 cell proliferation
SPP1 secreted phosphoprotein 1 NM_000582 2.49 cell adhesion
TGFBI transforming growth factor, beta-induced, 68 kDa NM_000358 2.28 cell adhesion/cell proliferation
*Fold Change: ZIC1 versus control vector.
doi:10.1371/journal.pone.0016916.t002
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PCR and Western blot in the surviving colonies. Then these stable
heterogeneous populations of cells were transferred into 6-well
plate to continuous selection with G418 for further studies.
Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl) -2-(4-
sulfophenyl)-2H -tetrazolium (MTS) reagents (Promega, Madison,
USA). Briefly, HCT116 and HT29 cells were cultured 24 hours in a
12-well plate and transiently transfected with pCDNA3.1-ZIC1 or
pCDNA3.1. Then these cells were plated in 96-well (2000–4000
cells/well) for 48 hours. After incubation with CellTiter 96 Aqueous
One Solution reagent for 1 hour, the absorbance was measured at
490 nm according to the instruction of MTS.
Colony formation assay
HCT116 and HT29 cells were cultured in 12- well plate
(1.0610
5 cells/well) for 24 hours and transfected with pCDNA3.1-
ZIC1 or pCDNA3.1 vector. After 48 hours, the transfectants were
re-plated in 6-well plate and cultured for 12–20 days in culture
medium containing G418 (400 mg/ml). Surviving colonies were
stained with Gentian Violer after methanol fixation and visible
colonies ($50 cells) were counted. The experiments were
performed in triplicate.
Cell apoptosis and cell-cycle analysis
Cell apoptosis assays were performed using the annexin V/PI
kit (Invitrogen) by flow cytometry analysis (FCA). Briefly,
transiently transfected cells (HCT116, HT29) were suspended in
annexin-binding buffer, Alexa Fluor 488 annexin V and PI
working solution were added in sequence. The stained cells were
finally analyzed by flow FACScan flow cytometry (Becton
Dickinson, USA) at 560 nm. Meanwhile, 2610
5 seeded cells were
exposed to the ultraviolet to induce apoptosis as a positive control.
Cell cycle distribution was detected by the Cycletest Plus DNA
Reagent kit (Becton Dickinson, USA). Briefly, transfected cells
were harvested and washed in PBS, cellular DNA was stained with
125 mg/mL propidium iodide for 20 minutes at 4uC in the dark.
The cells then were sorted by FACS Calibur and cell-cycle
distribution was determined using the ModFit LT software
(Phoenix, USA).
Western blot analysis
Total proteins were extracted from stably transfected cells using
RIPA lysis buffer. Lysates (20–60 mg) were resolved on SDS-
PAGE gel and transferred to PVDF membranes (Millipore,
Bedford, MA). The blots were probed with ZIC1 (1:500; Abcam),
Caspase3 (1:500; Sigma-Aldrich), Bcl-xl (1:500; Sigma), Bad
(1:500; Abnova), phospho-Bad (1:1000; Cell Signaling), Akt
(1:500; Abcam), phospho-Akt (1:2000;Cell Signaling), Erk1/2
(p44/42) (1:1000; Cell Signaling), phospho-Erk1/2 (p44/42)
(1:2000;Cell Signaling) and b-actin (1:2500, Multisciences Biotech)
antibodies. The blots were developed using a chemiluminescence
with Las-4000 Imaging System (Fujifilm, Japan).
cDNA microarray analysis and validation
Microarray studies were filtered to identify those that profiled gene
expression in ZIC1 or control vector stably transfected cell line
(HCT116) based on Affymetrix platform. cDNA was transcribed into
cRNA with aaUTP binding, which allow incorporation of fluorescent
dye Cy3 (pCDNA3.1-ZIC1) or Cy5 (pCDNA3.1). Finally, labeled
samples were hybridized to Agilent whole human genome containing
41,000 probes and transcripts. Duplicate experiments were carried
out. We selected log2 ratio $1o r#21 as the threshold for
upregulation or downregulation of gene expression.
The candidate ZIC1 target genes were classified into different
subgroups according to their biological functions (cell prolifera-
tion, migration, and angiogenesis, etc.). Ten representatives of
target genes: ANGPT2, CCNA2, GADD45B, IGFBP3, LAMB2,
LAMB3, MALAT1, PNMA2, RPA4 and TACSTD2 were verified
with qRT-PCR in ZIC1 or control vector tranfectants in HCT116
and HT29 cells.
Statistical analysis
Student’s t and Wilcoxon matched pairs tests were performed to
compare with two-independent data, while Chi-square or fisher
exact test methods to analysis categorical variables. A p,0.05 was
considered statistically significant.
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